New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 12, 2013
06:05 EDTCVS, MS, SNY, WMT, CS, BA, C, GSK, AAPLOn the Fly: Periodicals Wrap-Up
WALL STREET JOURNAL: Fed Vice-Chairwoman Janet Yellen offered a vigorous defense of the central bank's easy-money policies, suggesting she favors continuing them amid a slow economic recovery and disappointing job market, the Wall Street Journal reports...Behind David Einhorn's protestations on Apple (AAPL) is a novel way to return cash to shareholders. Einhorn, of hedge fund Greenlight Capital, proposed that Apple issue a special class of stock, which he called "perpetual preferred," that would carry a high dividend yield. But with some investors feeling more confident about the future, shareholder pressure is growing to put that cash to work, the Wall Street Journal reports...REUTERS: The NTSB is investigating whether tiny fiber-like formations, known as dendrites, inside lithium-ion batteries could have played a role in battery failures on two Boeing (BA) 787 Dreamliners last month, Reuters reports...The shifting nature of Africa's disease burden is luring Big Pharma (SNY, GSK) as new opportunities open up for treating chronic diseases afflicting the middle classes, rather than just fire-fighting infection. European companies, in particular, hope to reap rewards by investing early in a region where many of them already have historic commercial ties, Reuters reports...BLOOMBERG: Global investment banks based in Europe and the U.S., facing regulatory and cost-cutting pressures at home, are losing market share (CS, MS, C) in emerging economies to smaller domestic competitors, Bloomberg reports...In 2007, Wal-Mart Stores (WMT) planned to open as many as 2,000 in-house medical clinics by mid-2012. Today they have fewer than 130 clinics and is closing locations faster than itís opening them. CVS Caremark (CVS) has about 630 MinuteClinics and aims to have 1,500 within four years, Bloomberg reports.
News For AAPL;BA;SNY;GSK;CS;MS;C;WMT;CVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 >>
January 26, 2016
06:03 EDTAAPLVirnetX seeks $532M from Apple for alleged patent infringement, Bloomberg report
Subscribe for More Information
January 25, 2016
19:48 EDTAAPLApple design chief Jony Ive not unhappy with car project, CNET says
Subscribe for More Information
19:20 EDTAAPLApple reshuffles India operations after 'deep discounting' in quarter, ET says
Subscribe for More Information
16:49 EDTWMTMurphy USA announces $500M share buyback, shift in Walmart relationship
Subscribe for More Information
16:00 EDTC, AAPLOptions Update; January 25, 2016
Subscribe for More Information
15:24 EDTCVSExpress Scripts off highs after Clinton tweets critical NPR report
Subscribe for More Information
14:33 EDTBABoeing technical comments ahead of results
Subscribe for More Information
14:18 EDTAAPLApple volatility increases into Q1 and outlook
Subscribe for More Information
14:17 EDTAAPLVIX methodology for Apple VXAPL +3% to 39.17 into Q1 & outlook
Subscribe for More Information
14:06 EDTAAPLApple technical comments ahead of earnings, potential bearish pattern
There is a potential bearish head and shoulders top, which is most easily seen on a 3-year chart. The neckline for the pattern is at the $100 area on a closing basis, and in recent sessions the pattern has been both active and inactive as price crossed that line. If the news is bearish, a breakdown below $100 would see the pattern become active. Downside potential for the pattern would be to the $70 to $66 area. If the news is a bullish surprise, and sentiment has turned negative on the name which could add to short-cover demand, the counter-reaction up may be as large as pattern suggests is possible on the downside. It could mean in time a retaking of the $130 area or higher. The life high for the shares is at $134.54.
12:59 EDTAAPLApple executives unsatisfied with progress of 'Project Titan,' AppleInsider says
Subscribe for More Information
11:05 EDTGSKOncoMed price target lowered to $29 from $43 at Piper Jaffray
Subscribe for More Information
10:55 EDTSNYRegeneron slips after analyst says sell to avoid risk from Amgen patent suit
Shares of Regeneron Pharmaceuticals (REGN) fell in morning trading after an analyst at Chardan downgraded the stock to Sell, citing risk from a patent lawsuit in which the biopharmaceutical company is involved. CHARDAN SAYS SELL: Chardan Capital Markets analyst Gbola Amusa downgraded Regeneron to Sell from Neutral this morning, while reducing his price target on shares to $400 from $525. In a note to clients, Amusa said he believes that Regeneron is likely to face significant risks from the upcoming patent infringement case for Praluent. The suit could be a key driver of the company's share price performance in the near future, the analyst said. Regeneron, along with its partner Sanofi (SNY), launched Praluent in the U.S. last year, after the October 2014 filing of a patent infringement suit by Amgen (AMGN) relating to patents for "monoclonal antibodies that bind PCSK9," Amusa noted. The analyst believes that since Regeneron and Sanofi "likely" infringe Amgen's patents for Repatha, the Regeneron-Sanofi partnership could seek to settle the ahead of the trial by agreeing to pay 10%-20% or more of royalties to Amgen for U.S. Praluent sales. Amusa said that "such an outcome we estimate could transfer roughly $750M of operating income per year to Amgen." Further, Amusa said that catalysts surrounding the patent infringement trial are "likely to play out from late February to late March," and concedes that "both sides have good reasons to settle this case for a reasonable royalty." INCREASING COMPETITION: Amusa also noted that he sees increasing competitive risks in 2016 to Regeneron's Eylea from Novartis (NVS) and its partner Ophthotech (OPHT), which continue to progress Fovista into Phase III trials in wet AMD. WHAT'S NOTABLE: Roth Capital upgraded Regeneron to Buy from Neutral on January 19, based on valuation, as the firm said shares do not reflect the value of the company's upcoming catalysts. The firm also raised its price target to $555 from $543. The same day, Credit Suisse initiated Regeneron with a Neutral rating and $552 target. PRICE TARGET: Regeneron slipped 1.4% to $476.02 in morning trading.
10:03 EDTAAPLApple's iPhone 5se to likely come with faster A9/M9 chips, 9to5Mac reports
Subscribe for More Information
09:32 EDTAAPLApple Active equity options trading on open
Subscribe for More Information
09:03 EDTMSMorgan Stanley announces appointment of 156 managing directors
Subscribe for More Information
07:06 EDTAAPLApple volatility elevated into Q1 and outlook
Apple 1/29/16 call option implied volatility is at 57, February is at 38; compared to its 52-week range of 18 to 55, suggesting large near term price movement into the expected release of Q1 results on January 26.
06:53 EDTGSKGlaxo, Astra, J&J partner with universities in drug research fund, Reuters says
Subscribe for More Information
06:44 EDTAAPLApple to release new iPhone, iPad Air 3 in 1H16, AppleInsider says
Apple is planning to launch a 4-inch iPhone as well as the iPad Air 3 in the first half of the year, AppleInsider reports, citing KGI analyst Ming-Chi Kuo. Reference Link
05:51 EDTAAPLOptions expected to be active: TYC JCI TWTR SUNE AAPL PG HAL AMZN FB
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use